Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
ParcelBio
AddedMar 17, 2024
UpdatedJul 2, 2026
ParcelBio

ParcelBio

Seed

ParcelBio delivers customizable mRNA medicines with STAmP technology.

Founded
2023
Accelerator
Y Combinator logoY CombinatorW24
Overview
Compare
Fundraising
Employees
Website

ParcelBio, founded with the mission to revolutionize mRNA medicine delivery, focuses on developing programmable technology for safe and specific mRNA delivery to various cell types. Their proprietary STAmP technology stabilizes mRNA and employs a unique, interchangeable targeting mechanism, enabling the creation of fully customizable mRNA medicines. ParcelBio aims to advance the field of RNA therapeutics by providing innovative solutions that address diverse medical needs.

Notable figures associated with ParcelBio include experts in biotechnology and pharmaceutical development, although specific names are not provided. The company has garnered attention for its groundbreaking STAmP technology, which represents a significant advancement in the delivery of mRNA medicines. ParcelBio's impact lies in its potential to transform how mRNA therapies are developed and administered, offering new possibilities for treating a wide range of diseases.

ParcelBio - Similar Companies

Engage Bio logo

Engage Bio

Sensible Biotechnologies logo

Sensible Biotechnologies

sensible.bio

Cisterna Biologics logo

Cisterna Biologics

cisternabx.com

Serna Bio logo

Serna Bio

serna.bio

Sixfold Bioscience logo

Sixfold Bioscience

sixfold.bio

Rnaimmune logo

Rnaimmune

rnaimmune.com

Excepgen logo

Excepgen

excepgen.com

Mantra Bio logo

Mantra Bio

mantrabio.com

Strm.Bio logo

Strm.Bio

strm.bio

Pardes Biosciences logo

Pardes Biosciences

pardesbio.com

Andson Biotech logo

Andson Biotech

andsonbiotech.com

Parallel Bio logo

Parallel Bio

parallel.bio

Nuntius Therapeutics logo

Nuntius Therapeutics

nuntiustx.com

Ampersand Biomedicines logo

Ampersand Biomedicines

ampersand.bio

Intact Therapeutics logo

Intact Therapeutics

ParcelBio - Quick Facts

Who are ParcelBio's competitors?

Companies similar to ParcelBio include Engage Bio, Sensible Biotechnologies, Cisterna Biologics and Serna Bio.

When was ParcelBio founded?

ParcelBio was founded in 2023.

When was ParcelBio's last funding round?

ParcelBio's most recent funding round was for $500k (USD) in January 2024.

How much has ParcelBio raised to-date?

As of Jan 1, 2024, ParcelBio has raised a total of $500k (USD).

How many employees does ParcelBio have?

ParcelBio has 3 employees as of Apr 22, 2024.

ParcelBio - Classification

Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Software
Main Product
  • Mrna Medicines
Tags
  • Biotech
  • Healthtech